Hemogenyx Pharmaceuticals (HEMO) RNS Announcements

Add to Alert list
Date Time Source Announcement
16 Jan 2023 04:40 PM
RNS
Second Price Monitoring Extn
16 Jan 2023 04:35 PM
RNS
Price Monitoring Extension
13 Jan 2023 11:05 AM
RNS
Second Price Monitoring Extn
13 Jan 2023 11:00 AM
RNS
Price Monitoring Extension
12 Jan 2023 04:40 PM
RNS
Second Price Monitoring Extn
12 Jan 2023 04:35 PM
RNS
Price Monitoring Extension
12 Jan 2023 02:05 PM
RNS
Second Price Monitoring Extn
12 Jan 2023 02:00 PM
RNS
Price Monitoring Extension
10 Jan 2023 04:35 PM
RNS
Price Monitoring Extension
09 Jan 2023 09:05 AM
RNS
Second Price Monitoring Extn
09 Jan 2023 09:00 AM
RNS
Price Monitoring Extension
09 Jan 2023 07:00 AM
RNS
Single CBR Can Treat Multiple Viruses
05 Jan 2023 04:40 PM
RNS
Second Price Monitoring Extn
05 Jan 2023 04:35 PM
RNS
Price Monitoring Extension
05 Jan 2023 11:05 AM
RNS
Second Price Monitoring Extn
05 Jan 2023 11:00 AM
RNS
Price Monitoring Extension
04 Jan 2023 07:00 AM
RNS
HEMO-CAR-T Process Qualification Run Completed
12 Dec 2022 07:00 AM
RNS
HEMO-CAR-T First PQ Run Completed
18 Nov 2022 03:19 PM
RNS
HEMO-CAR-T Process Development Runs Completed
18 Nov 2022 11:05 AM
RNS
Second Price Monitoring Extn
18 Nov 2022 11:00 AM
RNS
Price Monitoring Extension
27 Oct 2022 04:40 PM
RNS
Second Price Monitoring Extn
27 Oct 2022 04:35 PM
RNS
Price Monitoring Extension
27 Oct 2022 02:05 PM
RNS
Second Price Monitoring Extn
27 Oct 2022 02:00 PM
RNS
Price Monitoring Extension
29 Sep 2022 08:00 AM
RNS
Half-year Report
01 Sep 2022 08:45 AM
RNS
Presentation at H.C. Wainwright Global Conference
22 Aug 2022 07:00 AM
RNS
Appointment of Director of Quality
15 Aug 2022 07:00 AM
RNS
Approval and Issuance of Antibody Patent
10 Aug 2022 07:00 AM
RNS
Appointment of Medical Director
09 Aug 2022 02:06 PM
RNS
Second Price Monitoring Extn
09 Aug 2022 02:00 PM
RNS
Price Monitoring Extension
13 Jul 2022 07:00 AM
RNS
New Custom R&D Facility Opening
08 Jul 2022 12:25 PM
RNS
Investor Webinar Recording
01 Jul 2022 12:19 PM
RNS
Change of Registered Office
30 Jun 2022 03:29 PM
RNS
Result of Annual General Meeting
27 Jun 2022 07:00 AM
RNS
Investor Webinar
07 Jun 2022 02:17 PM
RNS
Posting of Annual Report & Notice of AGM
30 May 2022 07:00 AM
RNS
Director/PDMR Shareholding
27 May 2022 02:05 PM
RNS
Second Price Monitoring Extn
27 May 2022 02:00 PM
RNS
Price Monitoring Extension
16 May 2022 07:00 AM
RNS
Immuno-Oncology Summit Europe Presentation
29 Apr 2022 05:39 PM
RNS
Final Results for the Year Ended 31 December 2021
21 Mar 2022 04:42 PM
RNS
Second Price Monitoring Extn
21 Mar 2022 04:36 PM
RNS
Price Monitoring Extension
21 Mar 2022 02:06 PM
RNS
Second Price Monitoring Extn
21 Mar 2022 02:01 PM
RNS
Price Monitoring Extension
16 Mar 2022 07:00 AM
RNS
CBR Update
04 Mar 2022 02:05 PM
RNS
Second Price Monitoring Extn
04 Mar 2022 02:00 PM
RNS
Price Monitoring Extension

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.

Hemogenyx Pharmaceuticals PLC is a preclinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases, like leukemia and lymphoma.

Hemo share price launched on LSE at 3p in 2017.

UK 100